The Top 5 Biosimilars Articles for the Week of December 2

The Center for Biosimilars® recaps the top stories for the week of December 2, 2019.
December 06, 2019


Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 2, 2019.

Number 5:  Writing in a perspective article in The New England Journal of Medicine, a noted critic of high pharmaceutical prices proposed targets for drug price negotiation.

Number 4: A recent study reports that pricing decisions for multiple sclerosis drugs are not the result of needing to recoup specific research and development costs. 

Number 3: The FDA released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins. 

Number 2: The European Commission has released a new report that highlights the role that biosimilars and generics will have in the well-being of European healthcare systems in the years ahead.

Number 1: Mylan and Biocon announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States. 

Finally, last week, our e-newsletter asked which group you think has the greatest responsibility to educate patients about biosimilars and biologics.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.